within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BG03_Pioglitazone;

model Pioglitazone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.83,
    Cl = 9.527777777777779e-07,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.0254,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005833333333333334,
    Tlag = 900,
    Vdp = 0.0109,
    k12 = 1.6944444444444442e-06,
    k21 = 1.6944444444444442e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pioglitazone</td></tr><tr><td>ATC code:</td><td>A10BG03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.43</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pioglitazone is a thiazolidinedione antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus either as monotherapy or in combination with other antidiabetic agents. It acts as an agonist at peroxisome proliferator-activated receptor gamma (PPAR-γ), reducing insulin resistance. Pioglitazone is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single oral dose administration.</p><h4>References</h4><ol><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=\"https://doi.org/10.2165/00003088-200544120-00002\">10.2165/00003088-200544120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16372821/\">https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Terrones-Gurrola, MCDR, et al., &amp; Vértiz-Hernández, AA (2023). Arsenic: A Perspective on Its Effect on Pioglitazone Bioavailability. <i>International journal of environmental research and public health</i> 20(3) –. DOI:<a href=\"https://doi.org/10.3390/ijerph20031901\">10.3390/ijerph20031901</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36767268/\">https://pubmed.ncbi.nlm.nih.gov/36767268</a></p></li><li><p>Yin, SJ, et al., &amp; Zhang, GL (2017). Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. <i>Pharmacogenetics and genomics</i> 27(4) 125–134. DOI:<a href=\"https://doi.org/10.1097/FPC.0000000000000265\">10.1097/FPC.0000000000000265</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28099407/\">https://pubmed.ncbi.nlm.nih.gov/28099407</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BG03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pioglitazone;
